Chemical Information | |
Antiviral agent ID | DrugRepV_6591 | |
Antiviral agent name | Elvitegravir | |
IUPAC Name | 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid | |
SMILES (canonical) | CC(C)C(CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O | |
SMILES (isomeric) | CC(C)[C@@H](CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O | |
Molecular Formula | C23H23ClFNO5 | |
Molecular Weight (g/mol) | 447.887 | |
InChl | InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1 | |
Common Name | Elvitegravir | |
Synonyms | 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | elvitégravir | EVG | GS 9137 | |
Structural Information | |
|
|
Clinical Information | |
Category | Antiinfectives For Systemic Use
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Infectious Disease
| |
Primary Indication (Disease) | Acquired immunodeficiency syndrome
| |
Secondary Indication | Human immunodeficiency virus (HIV) 1 G140S/Q148H (RAL) | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Drug concentration) | 5700 ± 1100 nM
| |
Secondary Indication (Cell based assay) | Single-round viral replication assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
Reference | Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH..Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants..Retrovirology. 2018 May 16;15(1):37. doi: 10.1186/s12977-018-0420-7. PMID:29769116
| |
Comment | Antiviral activities of Bictegravir and Cabotegravir against primary INSTI-resistant mutants.
| |